Pazopanib in the management of advanced soft tissue sarcomas

Lee D. Cranmer, Elizabeth T. Loggers, Seth M. Pollack

Research output: Contribution to journalReview articlepeer-review

21 Scopus citations


Therapy of soft tissue sarcomas represents an area of significant unmet need in oncology. Angiogenesis has been explored as a potential target both preclinically and clinically, with suggestions of activity. Pazopanib is a multitargeted tyrosine kinase inhibitor with prominent antiangiogenic effects. In a Phase II study, pazopanib demonstrated activity in strata enrolling patients with leiomyosarcomas, synovial sarcomas, or other sarcomas but not those enrolling adipocytic sarcomas. PALETTE, the pivotal Phase III trial, demonstrated improved progression-free survival versus placebo in pazopanib-treated patients previously treated for advanced soft tissue sarcomas. No survival benefit was observed, and adipocytic sarcomas were excluded. Health-related quality-of-life assessments indicated significant decrements in several areas affected by pazopanib toxicities, but no global deterioration. Cost-effectiveness analyses indicate that pazopanib therapy may or may not be cost-effective in different geographic settings. Pazopanib provides important proof-of-concept for antiangiogenic therapy in soft tissue sarcomas. Its use can be improved by further biological studies of its activity profile in sarcomas, studies of biological rational combinations, and clinicopathologic/biological correlative studies of activity to allow better drug targeting.

Original languageEnglish (US)
Pages (from-to)941-955
Number of pages15
JournalTherapeutics and Clinical Risk Management
StatePublished - Jun 9 2016


  • Angiogenesis
  • Cost-effectiveness
  • Pazopanib
  • Soft tissue sarcoma
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Safety Research
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)
  • Chemical Health and Safety


Dive into the research topics of 'Pazopanib in the management of advanced soft tissue sarcomas'. Together they form a unique fingerprint.

Cite this